CYSLTR2 and breast neoplasm: In aggressive breast tumors, this gene has been described as an independent prognostic factor in combination with CYSLTR1. 53 Selective agonist (NMLTC4)54 and antagonists, such as HAMI3379(ref. 55) or BayCysLT2,56 have been developed for CYSLTR2.